Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality -

Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality
Information type: Other primary research
Source: European Heart Journal
Specialities: Cardiovascular system disorders
Summary
Study of 279 Danish patients reported common use (59.9%) of drugs associated with torsades de pointes. A reduction in use of these drugs was seen 1 year after diagnosis vs previous year (28.4% vs 23.2%; P < 0.001), but increased 5 years after diagnosis (33.5%; P < 0.001).
UKMi comment
The study authors note that there is need for more awareness in prescribing patterns for this high-risk patient group, if adverse events are to be avoided
Related links: